PubRank

I Holen

Author PubWeight™ 31.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008 2.17
2 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001 1.83
3 Structural aspects of autophagy. Adv Exp Med Biol 1996 1.61
4 Dependence of hepatocytic autophagy on intracellularly sequestered calcium. J Biol Chem 1993 1.46
5 Non-selective autophagy. Semin Cell Biol 1990 1.42
6 Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004 1.25
7 The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002 1.25
8 From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies. Breast Cancer Res Treat 2006 1.15
9 Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol 2006 1.14
10 Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011 1.10
11 Expression and activity of ADAMTS-5 in synovium. Eur J Biochem 2001 1.05
12 Disruption of the cytokeratin cytoskeleton and inhibition of hepatocytic autophagy by okadaic acid. Exp Cell Res 1995 1.05
13 Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006 1.05
14 Anti-tumour effects of bisphosphonates--what have we learned from in vivo models? Curr Cancer Drug Targets 2009 1.04
15 The detection of circulating breast cancer cells in blood. J Clin Pathol 2004 0.96
16 Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J Clin Pathol 2006 0.96
17 Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012 0.91
18 Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010 0.91
19 Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin Exp Metastasis 2009 0.90
20 The metastatic microenvironment of breast cancer: clinical implications. Breast 2013 0.89
21 Hepatocytic autophagy. Biomed Biochim Acta 1991 0.87
22 Combined therapies of bone disease with bisphosphonates. Curr Pharm Des 2010 0.85
23 Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. Clin Exp Metastasis 2012 0.85
24 Protection by naringin and some other flavonoids of hepatocytic autophagy and endocytosis against inhibition by okadaic acid. J Biol Chem 1995 0.84
25 Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013 0.80
26 Imaging the effects of castration on bone turnover and hormone-independent prostate cancer colonization of bone. Prostate 2008 0.78
27 Morphological transformation and catalase activity of Syrian hamster embryo cells treated with hepatic peroxisome proliferators, TPA and nickel sulphate. Cell Biol Toxicol 1990 0.78
28 Bovine joint capsule and fibroblasts derived from joint capsule express aggrecanase activity. Matrix Biol 2000 0.78
29 Effects of adrenergic agonists and antagonists on autophagic activity in isolated rat liver cells. Biomed Biochim Acta 1991 0.76
30 Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells. J Cell Biochem 2008 0.75